Global Pneumonia Therapeutics

Pneumonia Therapeutics Comprehensive Study by Type (Vaccines, Anti-Infectives, Oxygen Therapy), Application (Hospital, Clinic, Medical Center, Other), Pneumonia Types (Hospital-acquired pneumonia (HAP), Community-acquired pneumonia (CAP), Ventilator-associated pneumonia (VAP)), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Players and Region - Global Market Outlook to 2026

Pneumonia Therapeutics Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Pneumonia Therapeutics Market Scope?
Pneumonia is a severe form of an acute lower respiratory infection that specifically affects one of both lungs. It generally caused by bacteria, viruses or fungi. To treat pneumonia a variety of therapeutic targets have been identified and numerous innovative therapeutic approaches demonstrated to improve lung injury in experimental preclinical studies.

The Pneumonia Therapeutics market study is being classified by Type (Vaccines, Anti-Infectives and Oxygen Therapy), by Application (Hospital, Clinic, Medical Center and Other) and major geographies with country level break-up.

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain competitive advantage through combined collaborations.

GlaxoSmithKline (United Kingdom), Merck & Co., Inc. (United States), Novartis (Switzerland), Pfizer Inc. (United States), AstraZeneca plc (United Kingdom), Bayer AG (Germany), Biotest (Germany), Tetraphase Pharmaceuticals Inc. (United States), Eli Lilly and Company (United States) and Sanofi S.A. (France) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Lupin Limited (India), Allergan plc (Ireland) and Baxter International Inc. (United States).

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Pneumonia Therapeutics market by Type, Application and Region.

On the basis of geography, the market of Pneumonia Therapeutics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

In February 2020, Merck has announced that the United States Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) for RECARBRIO (imipenem, cilastatin, and relebactam) to treat adult patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by certain susceptible Gram-negative microorganisms.


Influencing Market Trend
  • Increased Research and Development Activities
  • Rise in the Number of Diagnostic Centres and Hospitals

Market Drivers
  • Increased Prevalence of Community-Acquired Pneumonia
  • Improvements in the Diagnosis Methods
  • Robust Increase in the Distribution Channels

Opportunities
  • Increasing Awareness about Pneumonia Treatment among People
  • Growth in the Healthcare Centre Worldwide
  • Growing Number of Geriatric Population

Restraints
  • Increased Resistance of the Viruses to Various Antibiotics
  • Lack of Healthcare Infrastructure in Under Developed Countries

Challenges
  • Stringent Government Rules and Regulations
  • Lack of Skilled Professionals


Key Target Audience
Pneumonia Therapeutics Providers, Research Professionals, Emerging Companies and End-users

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Type
  • Vaccines
  • Anti-Infectives
  • Oxygen Therapy
By Application
  • Hospital
  • Clinic
  • Medical Center
  • Other
By Pneumonia Types
  • Hospital-acquired pneumonia (HAP)
  • Community-acquired pneumonia (CAP)
  • Ventilator-associated pneumonia (VAP)

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Community-Acquired Pneumonia
      • 3.2.2. Improvements in the Diagnosis Methods
      • 3.2.3. Robust Increase in the Distribution Channels
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
      • 3.3.2. Lack of Skilled Professionals
    • 3.4. Market Trends
      • 3.4.1. Increased Research and Development Activities
      • 3.4.2. Rise in the Number of Diagnostic Centres and Hospitals
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Pneumonia Therapeutics, by Type, Application, Pneumonia Types, Distribution Channel and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Pneumonia Therapeutics (Value)
      • 5.2.1. Global Pneumonia Therapeutics by: Type (Value)
        • 5.2.1.1. Vaccines
        • 5.2.1.2. Anti-Infectives
        • 5.2.1.3. Oxygen Therapy
      • 5.2.2. Global Pneumonia Therapeutics by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Clinic
        • 5.2.2.3. Medical Center
        • 5.2.2.4. Other
      • 5.2.3. Global Pneumonia Therapeutics by: Pneumonia Types (Value)
        • 5.2.3.1. Hospital-acquired pneumonia (HAP)
        • 5.2.3.2. Community-acquired pneumonia (CAP)
        • 5.2.3.3. Ventilator-associated pneumonia (VAP)
      • 5.2.4. Global Pneumonia Therapeutics by: Distribution Channel (Value)
        • 5.2.4.1. Hospital Pharmacies
        • 5.2.4.2. Retail Pharmacies
        • 5.2.4.3. Online Pharmacies
      • 5.2.5. Global Pneumonia Therapeutics Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Pneumonia Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck & Co., Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. AstraZeneca plc (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bayer AG (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Biotest (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Tetraphase Pharmaceuticals Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Eli Lilly and Company (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sanofi S.A. (France)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Pneumonia Therapeutics Sale, by Type, Application, Pneumonia Types, Distribution Channel and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Pneumonia Therapeutics (Value)
      • 7.2.1. Global Pneumonia Therapeutics by: Type (Value)
        • 7.2.1.1. Vaccines
        • 7.2.1.2. Anti-Infectives
        • 7.2.1.3. Oxygen Therapy
      • 7.2.2. Global Pneumonia Therapeutics by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Clinic
        • 7.2.2.3. Medical Center
        • 7.2.2.4. Other
      • 7.2.3. Global Pneumonia Therapeutics by: Pneumonia Types (Value)
        • 7.2.3.1. Hospital-acquired pneumonia (HAP)
        • 7.2.3.2. Community-acquired pneumonia (CAP)
        • 7.2.3.3. Ventilator-associated pneumonia (VAP)
      • 7.2.4. Global Pneumonia Therapeutics by: Distribution Channel (Value)
        • 7.2.4.1. Hospital Pharmacies
        • 7.2.4.2. Retail Pharmacies
        • 7.2.4.3. Online Pharmacies
      • 7.2.5. Global Pneumonia Therapeutics Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Pneumonia Therapeutics: by Type(USD Million)
  • Table 2. Pneumonia Therapeutics Vaccines , by Region USD Million (2015-2020)
  • Table 3. Pneumonia Therapeutics Anti-Infectives , by Region USD Million (2015-2020)
  • Table 4. Pneumonia Therapeutics Oxygen Therapy , by Region USD Million (2015-2020)
  • Table 5. Pneumonia Therapeutics: by Application(USD Million)
  • Table 6. Pneumonia Therapeutics Hospital , by Region USD Million (2015-2020)
  • Table 7. Pneumonia Therapeutics Clinic , by Region USD Million (2015-2020)
  • Table 8. Pneumonia Therapeutics Medical Center , by Region USD Million (2015-2020)
  • Table 9. Pneumonia Therapeutics Other , by Region USD Million (2015-2020)
  • Table 10. Pneumonia Therapeutics: by Pneumonia Types(USD Million)
  • Table 11. Pneumonia Therapeutics Hospital-acquired pneumonia (HAP) , by Region USD Million (2015-2020)
  • Table 12. Pneumonia Therapeutics Community-acquired pneumonia (CAP) , by Region USD Million (2015-2020)
  • Table 13. Pneumonia Therapeutics Ventilator-associated pneumonia (VAP) , by Region USD Million (2015-2020)
  • Table 14. Pneumonia Therapeutics: by Distribution Channel(USD Million)
  • Table 15. Pneumonia Therapeutics Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 16. Pneumonia Therapeutics Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 17. Pneumonia Therapeutics Online Pharmacies , by Region USD Million (2015-2020)
  • Table 18. South America Pneumonia Therapeutics, by Country USD Million (2015-2020)
  • Table 19. South America Pneumonia Therapeutics, by Type USD Million (2015-2020)
  • Table 20. South America Pneumonia Therapeutics, by Application USD Million (2015-2020)
  • Table 21. South America Pneumonia Therapeutics, by Pneumonia Types USD Million (2015-2020)
  • Table 22. South America Pneumonia Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 23. Brazil Pneumonia Therapeutics, by Type USD Million (2015-2020)
  • Table 24. Brazil Pneumonia Therapeutics, by Application USD Million (2015-2020)
  • Table 25. Brazil Pneumonia Therapeutics, by Pneumonia Types USD Million (2015-2020)
  • Table 26. Brazil Pneumonia Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 27. Argentina Pneumonia Therapeutics, by Type USD Million (2015-2020)
  • Table 28. Argentina Pneumonia Therapeutics, by Application USD Million (2015-2020)
  • Table 29. Argentina Pneumonia Therapeutics, by Pneumonia Types USD Million (2015-2020)
  • Table 30. Argentina Pneumonia Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 31. Rest of South America Pneumonia Therapeutics, by Type USD Million (2015-2020)
  • Table 32. Rest of South America Pneumonia Therapeutics, by Application USD Million (2015-2020)
  • Table 33. Rest of South America Pneumonia Therapeutics, by Pneumonia Types USD Million (2015-2020)
  • Table 34. Rest of South America Pneumonia Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 35. Asia Pacific Pneumonia Therapeutics, by Country USD Million (2015-2020)
  • Table 36. Asia Pacific Pneumonia Therapeutics, by Type USD Million (2015-2020)
  • Table 37. Asia Pacific Pneumonia Therapeutics, by Application USD Million (2015-2020)
  • Table 38. Asia Pacific Pneumonia Therapeutics, by Pneumonia Types USD Million (2015-2020)
  • Table 39. Asia Pacific Pneumonia Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 40. China Pneumonia Therapeutics, by Type USD Million (2015-2020)
  • Table 41. China Pneumonia Therapeutics, by Application USD Million (2015-2020)
  • Table 42. China Pneumonia Therapeutics, by Pneumonia Types USD Million (2015-2020)
  • Table 43. China Pneumonia Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 44. Japan Pneumonia Therapeutics, by Type USD Million (2015-2020)
  • Table 45. Japan Pneumonia Therapeutics, by Application USD Million (2015-2020)
  • Table 46. Japan Pneumonia Therapeutics, by Pneumonia Types USD Million (2015-2020)
  • Table 47. Japan Pneumonia Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 48. India Pneumonia Therapeutics, by Type USD Million (2015-2020)
  • Table 49. India Pneumonia Therapeutics, by Application USD Million (2015-2020)
  • Table 50. India Pneumonia Therapeutics, by Pneumonia Types USD Million (2015-2020)
  • Table 51. India Pneumonia Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 52. South Korea Pneumonia Therapeutics, by Type USD Million (2015-2020)
  • Table 53. South Korea Pneumonia Therapeutics, by Application USD Million (2015-2020)
  • Table 54. South Korea Pneumonia Therapeutics, by Pneumonia Types USD Million (2015-2020)
  • Table 55. South Korea Pneumonia Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 56. Taiwan Pneumonia Therapeutics, by Type USD Million (2015-2020)
  • Table 57. Taiwan Pneumonia Therapeutics, by Application USD Million (2015-2020)
  • Table 58. Taiwan Pneumonia Therapeutics, by Pneumonia Types USD Million (2015-2020)
  • Table 59. Taiwan Pneumonia Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 60. Australia Pneumonia Therapeutics, by Type USD Million (2015-2020)
  • Table 61. Australia Pneumonia Therapeutics, by Application USD Million (2015-2020)
  • Table 62. Australia Pneumonia Therapeutics, by Pneumonia Types USD Million (2015-2020)
  • Table 63. Australia Pneumonia Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Pneumonia Therapeutics, by Type USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Pneumonia Therapeutics, by Application USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Pneumonia Therapeutics, by Pneumonia Types USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Pneumonia Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 68. Europe Pneumonia Therapeutics, by Country USD Million (2015-2020)
  • Table 69. Europe Pneumonia Therapeutics, by Type USD Million (2015-2020)
  • Table 70. Europe Pneumonia Therapeutics, by Application USD Million (2015-2020)
  • Table 71. Europe Pneumonia Therapeutics, by Pneumonia Types USD Million (2015-2020)
  • Table 72. Europe Pneumonia Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 73. Germany Pneumonia Therapeutics, by Type USD Million (2015-2020)
  • Table 74. Germany Pneumonia Therapeutics, by Application USD Million (2015-2020)
  • Table 75. Germany Pneumonia Therapeutics, by Pneumonia Types USD Million (2015-2020)
  • Table 76. Germany Pneumonia Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 77. France Pneumonia Therapeutics, by Type USD Million (2015-2020)
  • Table 78. France Pneumonia Therapeutics, by Application USD Million (2015-2020)
  • Table 79. France Pneumonia Therapeutics, by Pneumonia Types USD Million (2015-2020)
  • Table 80. France Pneumonia Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 81. Italy Pneumonia Therapeutics, by Type USD Million (2015-2020)
  • Table 82. Italy Pneumonia Therapeutics, by Application USD Million (2015-2020)
  • Table 83. Italy Pneumonia Therapeutics, by Pneumonia Types USD Million (2015-2020)
  • Table 84. Italy Pneumonia Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 85. United Kingdom Pneumonia Therapeutics, by Type USD Million (2015-2020)
  • Table 86. United Kingdom Pneumonia Therapeutics, by Application USD Million (2015-2020)
  • Table 87. United Kingdom Pneumonia Therapeutics, by Pneumonia Types USD Million (2015-2020)
  • Table 88. United Kingdom Pneumonia Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 89. Netherlands Pneumonia Therapeutics, by Type USD Million (2015-2020)
  • Table 90. Netherlands Pneumonia Therapeutics, by Application USD Million (2015-2020)
  • Table 91. Netherlands Pneumonia Therapeutics, by Pneumonia Types USD Million (2015-2020)
  • Table 92. Netherlands Pneumonia Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 93. Rest of Europe Pneumonia Therapeutics, by Type USD Million (2015-2020)
  • Table 94. Rest of Europe Pneumonia Therapeutics, by Application USD Million (2015-2020)
  • Table 95. Rest of Europe Pneumonia Therapeutics, by Pneumonia Types USD Million (2015-2020)
  • Table 96. Rest of Europe Pneumonia Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 97. MEA Pneumonia Therapeutics, by Country USD Million (2015-2020)
  • Table 98. MEA Pneumonia Therapeutics, by Type USD Million (2015-2020)
  • Table 99. MEA Pneumonia Therapeutics, by Application USD Million (2015-2020)
  • Table 100. MEA Pneumonia Therapeutics, by Pneumonia Types USD Million (2015-2020)
  • Table 101. MEA Pneumonia Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 102. Middle East Pneumonia Therapeutics, by Type USD Million (2015-2020)
  • Table 103. Middle East Pneumonia Therapeutics, by Application USD Million (2015-2020)
  • Table 104. Middle East Pneumonia Therapeutics, by Pneumonia Types USD Million (2015-2020)
  • Table 105. Middle East Pneumonia Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 106. Africa Pneumonia Therapeutics, by Type USD Million (2015-2020)
  • Table 107. Africa Pneumonia Therapeutics, by Application USD Million (2015-2020)
  • Table 108. Africa Pneumonia Therapeutics, by Pneumonia Types USD Million (2015-2020)
  • Table 109. Africa Pneumonia Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 110. North America Pneumonia Therapeutics, by Country USD Million (2015-2020)
  • Table 111. North America Pneumonia Therapeutics, by Type USD Million (2015-2020)
  • Table 112. North America Pneumonia Therapeutics, by Application USD Million (2015-2020)
  • Table 113. North America Pneumonia Therapeutics, by Pneumonia Types USD Million (2015-2020)
  • Table 114. North America Pneumonia Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 115. United States Pneumonia Therapeutics, by Type USD Million (2015-2020)
  • Table 116. United States Pneumonia Therapeutics, by Application USD Million (2015-2020)
  • Table 117. United States Pneumonia Therapeutics, by Pneumonia Types USD Million (2015-2020)
  • Table 118. United States Pneumonia Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 119. Canada Pneumonia Therapeutics, by Type USD Million (2015-2020)
  • Table 120. Canada Pneumonia Therapeutics, by Application USD Million (2015-2020)
  • Table 121. Canada Pneumonia Therapeutics, by Pneumonia Types USD Million (2015-2020)
  • Table 122. Canada Pneumonia Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 123. Mexico Pneumonia Therapeutics, by Type USD Million (2015-2020)
  • Table 124. Mexico Pneumonia Therapeutics, by Application USD Million (2015-2020)
  • Table 125. Mexico Pneumonia Therapeutics, by Pneumonia Types USD Million (2015-2020)
  • Table 126. Mexico Pneumonia Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Pneumonia Therapeutics: by Type(USD Million)
  • Table 138. Pneumonia Therapeutics Vaccines , by Region USD Million (2021-2026)
  • Table 139. Pneumonia Therapeutics Anti-Infectives , by Region USD Million (2021-2026)
  • Table 140. Pneumonia Therapeutics Oxygen Therapy , by Region USD Million (2021-2026)
  • Table 141. Pneumonia Therapeutics: by Application(USD Million)
  • Table 142. Pneumonia Therapeutics Hospital , by Region USD Million (2021-2026)
  • Table 143. Pneumonia Therapeutics Clinic , by Region USD Million (2021-2026)
  • Table 144. Pneumonia Therapeutics Medical Center , by Region USD Million (2021-2026)
  • Table 145. Pneumonia Therapeutics Other , by Region USD Million (2021-2026)
  • Table 146. Pneumonia Therapeutics: by Pneumonia Types(USD Million)
  • Table 147. Pneumonia Therapeutics Hospital-acquired pneumonia (HAP) , by Region USD Million (2021-2026)
  • Table 148. Pneumonia Therapeutics Community-acquired pneumonia (CAP) , by Region USD Million (2021-2026)
  • Table 149. Pneumonia Therapeutics Ventilator-associated pneumonia (VAP) , by Region USD Million (2021-2026)
  • Table 150. Pneumonia Therapeutics: by Distribution Channel(USD Million)
  • Table 151. Pneumonia Therapeutics Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 152. Pneumonia Therapeutics Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 153. Pneumonia Therapeutics Online Pharmacies , by Region USD Million (2021-2026)
  • Table 154. South America Pneumonia Therapeutics, by Country USD Million (2021-2026)
  • Table 155. South America Pneumonia Therapeutics, by Type USD Million (2021-2026)
  • Table 156. South America Pneumonia Therapeutics, by Application USD Million (2021-2026)
  • Table 157. South America Pneumonia Therapeutics, by Pneumonia Types USD Million (2021-2026)
  • Table 158. South America Pneumonia Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 159. Brazil Pneumonia Therapeutics, by Type USD Million (2021-2026)
  • Table 160. Brazil Pneumonia Therapeutics, by Application USD Million (2021-2026)
  • Table 161. Brazil Pneumonia Therapeutics, by Pneumonia Types USD Million (2021-2026)
  • Table 162. Brazil Pneumonia Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 163. Argentina Pneumonia Therapeutics, by Type USD Million (2021-2026)
  • Table 164. Argentina Pneumonia Therapeutics, by Application USD Million (2021-2026)
  • Table 165. Argentina Pneumonia Therapeutics, by Pneumonia Types USD Million (2021-2026)
  • Table 166. Argentina Pneumonia Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 167. Rest of South America Pneumonia Therapeutics, by Type USD Million (2021-2026)
  • Table 168. Rest of South America Pneumonia Therapeutics, by Application USD Million (2021-2026)
  • Table 169. Rest of South America Pneumonia Therapeutics, by Pneumonia Types USD Million (2021-2026)
  • Table 170. Rest of South America Pneumonia Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 171. Asia Pacific Pneumonia Therapeutics, by Country USD Million (2021-2026)
  • Table 172. Asia Pacific Pneumonia Therapeutics, by Type USD Million (2021-2026)
  • Table 173. Asia Pacific Pneumonia Therapeutics, by Application USD Million (2021-2026)
  • Table 174. Asia Pacific Pneumonia Therapeutics, by Pneumonia Types USD Million (2021-2026)
  • Table 175. Asia Pacific Pneumonia Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 176. China Pneumonia Therapeutics, by Type USD Million (2021-2026)
  • Table 177. China Pneumonia Therapeutics, by Application USD Million (2021-2026)
  • Table 178. China Pneumonia Therapeutics, by Pneumonia Types USD Million (2021-2026)
  • Table 179. China Pneumonia Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 180. Japan Pneumonia Therapeutics, by Type USD Million (2021-2026)
  • Table 181. Japan Pneumonia Therapeutics, by Application USD Million (2021-2026)
  • Table 182. Japan Pneumonia Therapeutics, by Pneumonia Types USD Million (2021-2026)
  • Table 183. Japan Pneumonia Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 184. India Pneumonia Therapeutics, by Type USD Million (2021-2026)
  • Table 185. India Pneumonia Therapeutics, by Application USD Million (2021-2026)
  • Table 186. India Pneumonia Therapeutics, by Pneumonia Types USD Million (2021-2026)
  • Table 187. India Pneumonia Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 188. South Korea Pneumonia Therapeutics, by Type USD Million (2021-2026)
  • Table 189. South Korea Pneumonia Therapeutics, by Application USD Million (2021-2026)
  • Table 190. South Korea Pneumonia Therapeutics, by Pneumonia Types USD Million (2021-2026)
  • Table 191. South Korea Pneumonia Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 192. Taiwan Pneumonia Therapeutics, by Type USD Million (2021-2026)
  • Table 193. Taiwan Pneumonia Therapeutics, by Application USD Million (2021-2026)
  • Table 194. Taiwan Pneumonia Therapeutics, by Pneumonia Types USD Million (2021-2026)
  • Table 195. Taiwan Pneumonia Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 196. Australia Pneumonia Therapeutics, by Type USD Million (2021-2026)
  • Table 197. Australia Pneumonia Therapeutics, by Application USD Million (2021-2026)
  • Table 198. Australia Pneumonia Therapeutics, by Pneumonia Types USD Million (2021-2026)
  • Table 199. Australia Pneumonia Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 200. Rest of Asia-Pacific Pneumonia Therapeutics, by Type USD Million (2021-2026)
  • Table 201. Rest of Asia-Pacific Pneumonia Therapeutics, by Application USD Million (2021-2026)
  • Table 202. Rest of Asia-Pacific Pneumonia Therapeutics, by Pneumonia Types USD Million (2021-2026)
  • Table 203. Rest of Asia-Pacific Pneumonia Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 204. Europe Pneumonia Therapeutics, by Country USD Million (2021-2026)
  • Table 205. Europe Pneumonia Therapeutics, by Type USD Million (2021-2026)
  • Table 206. Europe Pneumonia Therapeutics, by Application USD Million (2021-2026)
  • Table 207. Europe Pneumonia Therapeutics, by Pneumonia Types USD Million (2021-2026)
  • Table 208. Europe Pneumonia Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 209. Germany Pneumonia Therapeutics, by Type USD Million (2021-2026)
  • Table 210. Germany Pneumonia Therapeutics, by Application USD Million (2021-2026)
  • Table 211. Germany Pneumonia Therapeutics, by Pneumonia Types USD Million (2021-2026)
  • Table 212. Germany Pneumonia Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 213. France Pneumonia Therapeutics, by Type USD Million (2021-2026)
  • Table 214. France Pneumonia Therapeutics, by Application USD Million (2021-2026)
  • Table 215. France Pneumonia Therapeutics, by Pneumonia Types USD Million (2021-2026)
  • Table 216. France Pneumonia Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 217. Italy Pneumonia Therapeutics, by Type USD Million (2021-2026)
  • Table 218. Italy Pneumonia Therapeutics, by Application USD Million (2021-2026)
  • Table 219. Italy Pneumonia Therapeutics, by Pneumonia Types USD Million (2021-2026)
  • Table 220. Italy Pneumonia Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 221. United Kingdom Pneumonia Therapeutics, by Type USD Million (2021-2026)
  • Table 222. United Kingdom Pneumonia Therapeutics, by Application USD Million (2021-2026)
  • Table 223. United Kingdom Pneumonia Therapeutics, by Pneumonia Types USD Million (2021-2026)
  • Table 224. United Kingdom Pneumonia Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 225. Netherlands Pneumonia Therapeutics, by Type USD Million (2021-2026)
  • Table 226. Netherlands Pneumonia Therapeutics, by Application USD Million (2021-2026)
  • Table 227. Netherlands Pneumonia Therapeutics, by Pneumonia Types USD Million (2021-2026)
  • Table 228. Netherlands Pneumonia Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 229. Rest of Europe Pneumonia Therapeutics, by Type USD Million (2021-2026)
  • Table 230. Rest of Europe Pneumonia Therapeutics, by Application USD Million (2021-2026)
  • Table 231. Rest of Europe Pneumonia Therapeutics, by Pneumonia Types USD Million (2021-2026)
  • Table 232. Rest of Europe Pneumonia Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 233. MEA Pneumonia Therapeutics, by Country USD Million (2021-2026)
  • Table 234. MEA Pneumonia Therapeutics, by Type USD Million (2021-2026)
  • Table 235. MEA Pneumonia Therapeutics, by Application USD Million (2021-2026)
  • Table 236. MEA Pneumonia Therapeutics, by Pneumonia Types USD Million (2021-2026)
  • Table 237. MEA Pneumonia Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 238. Middle East Pneumonia Therapeutics, by Type USD Million (2021-2026)
  • Table 239. Middle East Pneumonia Therapeutics, by Application USD Million (2021-2026)
  • Table 240. Middle East Pneumonia Therapeutics, by Pneumonia Types USD Million (2021-2026)
  • Table 241. Middle East Pneumonia Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 242. Africa Pneumonia Therapeutics, by Type USD Million (2021-2026)
  • Table 243. Africa Pneumonia Therapeutics, by Application USD Million (2021-2026)
  • Table 244. Africa Pneumonia Therapeutics, by Pneumonia Types USD Million (2021-2026)
  • Table 245. Africa Pneumonia Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 246. North America Pneumonia Therapeutics, by Country USD Million (2021-2026)
  • Table 247. North America Pneumonia Therapeutics, by Type USD Million (2021-2026)
  • Table 248. North America Pneumonia Therapeutics, by Application USD Million (2021-2026)
  • Table 249. North America Pneumonia Therapeutics, by Pneumonia Types USD Million (2021-2026)
  • Table 250. North America Pneumonia Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 251. United States Pneumonia Therapeutics, by Type USD Million (2021-2026)
  • Table 252. United States Pneumonia Therapeutics, by Application USD Million (2021-2026)
  • Table 253. United States Pneumonia Therapeutics, by Pneumonia Types USD Million (2021-2026)
  • Table 254. United States Pneumonia Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 255. Canada Pneumonia Therapeutics, by Type USD Million (2021-2026)
  • Table 256. Canada Pneumonia Therapeutics, by Application USD Million (2021-2026)
  • Table 257. Canada Pneumonia Therapeutics, by Pneumonia Types USD Million (2021-2026)
  • Table 258. Canada Pneumonia Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 259. Mexico Pneumonia Therapeutics, by Type USD Million (2021-2026)
  • Table 260. Mexico Pneumonia Therapeutics, by Application USD Million (2021-2026)
  • Table 261. Mexico Pneumonia Therapeutics, by Pneumonia Types USD Million (2021-2026)
  • Table 262. Mexico Pneumonia Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 263. Research Programs/Design for This Report
  • Table 264. Key Data Information from Secondary Sources
  • Table 265. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Pneumonia Therapeutics: by Type USD Million (2015-2020)
  • Figure 5. Global Pneumonia Therapeutics: by Application USD Million (2015-2020)
  • Figure 6. Global Pneumonia Therapeutics: by Pneumonia Types USD Million (2015-2020)
  • Figure 7. Global Pneumonia Therapeutics: by Distribution Channel USD Million (2015-2020)
  • Figure 8. South America Pneumonia Therapeutics Share (%), by Country
  • Figure 9. Asia Pacific Pneumonia Therapeutics Share (%), by Country
  • Figure 10. Europe Pneumonia Therapeutics Share (%), by Country
  • Figure 11. MEA Pneumonia Therapeutics Share (%), by Country
  • Figure 12. North America Pneumonia Therapeutics Share (%), by Country
  • Figure 13. Global Pneumonia Therapeutics share by Players 2020 (%)
  • Figure 14. Global Pneumonia Therapeutics share by Players (Top 3) 2020(%)
  • Figure 15. Global Pneumonia Therapeutics share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2020
  • Figure 19. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Merck & Co., Inc. (United States) Revenue: by Geography 2020
  • Figure 21. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. Novartis (Switzerland) Revenue: by Geography 2020
  • Figure 23. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 25. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. AstraZeneca plc (United Kingdom) Revenue: by Geography 2020
  • Figure 27. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Bayer AG (Germany) Revenue: by Geography 2020
  • Figure 29. Biotest (Germany) Revenue, Net Income and Gross profit
  • Figure 30. Biotest (Germany) Revenue: by Geography 2020
  • Figure 31. Tetraphase Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Tetraphase Pharmaceuticals Inc. (United States) Revenue: by Geography 2020
  • Figure 33. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 34. Eli Lilly and Company (United States) Revenue: by Geography 2020
  • Figure 35. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 36. Sanofi S.A. (France) Revenue: by Geography 2020
  • Figure 37. Global Pneumonia Therapeutics: by Type USD Million (2021-2026)
  • Figure 38. Global Pneumonia Therapeutics: by Application USD Million (2021-2026)
  • Figure 39. Global Pneumonia Therapeutics: by Pneumonia Types USD Million (2021-2026)
  • Figure 40. Global Pneumonia Therapeutics: by Distribution Channel USD Million (2021-2026)
  • Figure 41. South America Pneumonia Therapeutics Share (%), by Country
  • Figure 42. Asia Pacific Pneumonia Therapeutics Share (%), by Country
  • Figure 43. Europe Pneumonia Therapeutics Share (%), by Country
  • Figure 44. MEA Pneumonia Therapeutics Share (%), by Country
  • Figure 45. North America Pneumonia Therapeutics Share (%), by Country
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline (United Kingdom)
  • Merck & Co., Inc. (United States)
  • Novartis (Switzerland)
  • Pfizer Inc. (United States)
  • AstraZeneca plc (United Kingdom)
  • Bayer AG (Germany)
  • Biotest (Germany)
  • Tetraphase Pharmaceuticals Inc. (United States)
  • Eli Lilly and Company (United States)
  • Sanofi S.A. (France)
Additional players considered in the study are as follows:
Lupin Limited (India) , Allergan plc (Ireland) , Baxter International Inc. (United States)
Select User Access Type

Key Highlights of Report


Sep 2021 213 Pages 80 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Pneumonia Therapeutics Quantitative research analysis
Global Pneumonia Therapeutics Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Global Pneumonia Therapeutics market is expected to see a growth of % during projected year 2020 to 2026.
The prominent players of Global Pneumonia Therapeutics market are GlaxoSmithKline (United Kingdom), Merck & Co., Inc. (United States), Novartis (Switzerland), Pfizer Inc. (United States), AstraZeneca plc (United Kingdom), Bayer AG (Germany), Biotest (Germany), Tetraphase Pharmaceuticals Inc. (United States), Eli Lilly and Company (United States) and Sanofi S.A. (France), to name a few.
In this highly competitive & fast evolving Pneumonia Therapeutics industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.

Know More About Global Pneumonia Therapeutics Report?

Have a Query? Click Here

Other Related Reports

Bone Morphogenetic Protein Comprehensive Study by Type (Recombinant Human Bone Morphogenetic Protein (rhBMP) - 2, Recombinant Human Bone Morphogenetic Protein (rhBMP) -7), Application (Spinal Fusion,...
$ 3350
Spasticity Treatment Comprehensive Study by Type (Physical Treatment, Medicine Treatment), Application (Children, Adults), End User (Hospital, Research Laboratories, Others) Players and Region - Glob...
$ 3500
Tuberculosis Drug Comprehensive Study by Type (First-line Anti-TB Drugs, Second-line Anti-TB Drugs), Application (Active TB, Latent TB), End User (Hospital, Clinic, Durgstore), Testing (TB skin test ...
$ 3350
Inflammatory Bowel Disease Comprehensive Study by Type (Anti-inflammatory Biologics, Non-Steroidal Anti-inflammatory drugs (NSAIDs), Corticosteroids), Application (Hospital, Drugs Stores), Route of A...
$ 3450
Organ Transplant Immunosuppressant Drugs Comprehensive Study by Type (Chemical Composition, Fungal Product, Biologics), Application (Liver Transplant, Kidney Transplant, Other Organ Transplant), Drug...
$ 3650
Tissue Engineering Comprehensive Study by Type (Synthetic Materials, Biologically Derived Materials, Others), Application (Orthopedics, Musculoskeletal & Spine, Neurology, Cardiology & Vascular, Skin...
$ 3450